|
Non-Small Cell Lung Carcinoma
|
0.550 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Endometrial Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
For example, aberrant hypermethylation of the CHFR gene is correlated with cellular sensitivity to microtubule inhibitors, and this may be useful in treatment of type I endometrial cancer.
|
19787208 |
2009 |
|
Stomach Neoplasms
|
0.320 |
GeneticVariation
|
group |
BEFREE |
Eight of 12 (66.7%) gastric cancer cell lines and 19/43 (44.2%) primary gastric tumors showed CHFR methylation.
|
15201973 |
2004 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although studies have shown that CHFR is relevant to tumorigenesis, no previous report has investigated whether polymorphisms in the CHFR gene are associated with the risk of cancer development.
|
18079053 |
2008 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger domains) is silenced in various human cancers by promoter hypermethylation, suggesting that CHFR is a tumor suppressor.
|
19448676 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We preselected three tumor suppressor genes and one locus of interest; CHFR, ID4, RECK, and MINT1.
|
21551253 |
2011 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although studies have shown that CHFR is relevant to tumorigenesis, no previous report has investigated whether polymorphisms in the CHFR gene are associated with the risk of cancer development.
|
18079053 |
2008 |
|
Colorectal Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
These results reveal for the first time that polymorphisms in the CHFR gene are associated with colorectal cancer susceptibility.
|
18079053 |
2008 |
|
Squamous cell carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Reduced CHFR expression was associated with EGFR exon19/21 mutations in adenocarcinoma OR 0.23 (95%CI: 0.06-0.88) and male gender in squamous cell carcinoma (OR 0.46 (95%CI 0.23-0.92), p = 0.02).
|
25477232 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
These results reveal for the first time that polymorphisms in the CHFR gene are associated with colorectal cancer susceptibility.
|
18079053 |
2008 |
|
Malignant neoplasm of breast
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined the methylation status of the promoter region of CHFR gene in 110 primary breast cancers.
|
16502017 |
2006 |
|
Malignant neoplasm of endometrium
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
For example, aberrant hypermethylation of the CHFR gene is correlated with cellular sensitivity to microtubule inhibitors, and this may be useful in treatment of type I endometrial cancer.
|
19787208 |
2009 |
|
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
|
16502017 |
2006 |
|
Colorectal Neoplasms
|
0.020 |
GeneticVariation
|
group |
LHGDN |
Coding region polymorphisms in the CHFR mitotic stress checkpoint gene are associated with colorectal cancer risk.
|
18079053 |
2008 |
|
Metastatic non-small cell lung cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
|
20705357 |
2011 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
However, there was no significant correlation between methylation status of CHFR gene and the clinicopathologic parameters of gastric cancer, including age, gender, tumor size, clinical stage, Borrman type, tumor invasion depth, differentiation, and lymph node metastasis (P > 0.05).
|
20109344 |
2010 |
|
Adenomatous Polyposis Coli
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Neither APC mutation status nor CHFR methylation status correlated with efficacy in the CIMP-high CRC cohort.
|
29069279 |
2018 |
|
Cervical Adenocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer.
|
17786301 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.550 |
Biomarker
|
disease |
CTD_human |
A panel of seven human EGFR wild-type NSCLC cell lines was characterized for their sensitivity to sequential treatment with cisplatin and erlotinib, and the results were correlated with CHFR.
|
20705357 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.550 |
Biomarker
|
disease |
BEFREE |
A panel of seven human EGFR wild-type NSCLC cell lines was characterized for their sensitivity to sequential treatment with cisplatin and erlotinib, and the results were correlated with CHFR.
|
20705357 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.550 |
Biomarker
|
disease |
BEFREE |
Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
|
20855974 |
2010 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |